Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), enabling its use prior to chemotherapy for eligible ...
A hidden TP53 mutation in donor sperm raises concerns about gaps in genetic screening and long-term cancer risk in ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
A recent article in JAMA Internal Medicine describes a common genetic mutation found in many breast cancer patients who do ...
The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...
TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.
The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...
Researchers have demonstrated in the WISDOM trial that integrating criteria-independent genetic testing into routine breast ...
Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.
Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...
Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results